SCHEMBL12723907

SCHEMBL12723907

CCOP(=O)(OCC)c1cc(F)ccc1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.43
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
KEAP1 Q14145 1/20 0.36
KDM4E B2RXH2 4/20 0.35
LMNA P02545 3/20 0.34
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CA12 O43570 3/20 0.33
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
CA9 Q16790 3/20 0.33
HDAC1 Q13547 2/20 0.33
GAA P10253 2/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12723909 0.87 POLB (0.43) POLBALDH1A1MEN1KMT2AKEAP1
SCHEMBL1629451 0.83 POLB (0.45) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL1631353 0.81 POLB (0.44) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL2720324 0.81 POLB (0.44) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL12762217 0.81 POLB (0.51) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL1629971 0.80 POLB (0.43) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL3242752 0.80 POLB (0.43) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL12723933 0.80 LMNA (0.43) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL27649699 0.78 POLB (0.41) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL23528119 0.76 GAA (0.44) POLBALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932240-B2 Phosphadiazine HCV polymerase inhibitors IV IDENIX PHARMACEUTICALS, INC. (US) 2011-04-26 US disclosed
US-7932240-B2 Phosphadiazine HCV polymerase inhibitors IV IDENIX PHARMACEUTICALS, INC. (US) 2011-04-26 US disclosed
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
WO-2009032180-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV POLI, ITPA, POLR2H POLB 28/4885ALDH1A1 1722/4885MEN1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.